Drug firm Lupin on Monday said it has launched Rufinamide Tablets, an anticonvulsant medication, in the American market.
The company has launched the product, a generic version of Eisai Inc's Banzel tablets, in 200 mg and 400 mg strengths, the drug firm said in a statement.
As per IQVIA data, Rufinamide tablets had estimated annual sales of $138 million in the U.S.
Shares of the company were trading 0.81% down at Rs 769.05 apiece on the BSE.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Hyderabad Bound Air India Express Flight Makes Emergency Landing In Vizag Over Suspected Bird Hit


India's Tablet Market Dips 32.3% In First Half Of 2025, Samsung Tops Chart


Trump Sets Sept 29 Deadline For J&J, Pfizer, Other Pharma Firms To Lower US Drug Prices


Sun Pharma, Lupin, Dr. Reddy's Recall Products In US market
